

Tara A Russell

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4268843/tara-a-russell-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

1,162
citations

21
h-index

33
g-index

46
ext. papers

1,247
ext. citations

4
avg, IF

3.68
L-index

#	Paper	IF	Citations
46	Tumor-targeting Salmonella typhimurium A1-R in combination with doxorubicin eradicate soft tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016 , 7, 12783-90	3.3	99
45	Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2016 , 7, 47556-47564	3.3	87
44	Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016 , 7, 85929-85936	3.3	74
43	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2016 , 7, 71737-71743	3.3	71
42	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2017 , 8, 85516-85525	3.3	56
41	Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 2314-2319	4.7	52
40	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018 , 417, 168-173	9.9	47
39	Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Cell Cycle</i> , 2017 , 16, 1164-1170	4.7	45
38	Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. <i>Oncotarget</i> , 2017 , 8, 8035-8042	3.3	44
37	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , 2017 , 8, 62111-62119	3.3	42
36	Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , 2017 , 16, 1288-1294	4.7	41
35	Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017 , 16, 1288-1294	4.7	34
34	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. <i>Oncotarget</i> , 2018 , 9, 915-923	3.3	34
33	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , 2018 , 17, 356-361	4.7	33
32	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , 2017 , 8, 103129-103136	3.3	32
31	Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. <i>Journal of Cellular Biochemistry</i> , 2017 , 118, 361-365	4.7	30
30	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , 2017 , 16, 1063-1069	4.7	26

29	Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 3537-3544	4.7	26
28	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , 2018 , 9, 11119-11233	3.3	23
27	Tumor-targeting Salmonella typhimurium A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 497, 1055-1061	3.4	22
26	Distinction of Risk Factors for Superficial vs Organ-Space Surgical Site Infections After Pancreatic Surgery. <i>JAMA Surgery</i> , 2017 , 152, 1023-1029	5.4	21
25	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018 , 9, 19263-19272	3.2	19
24	Combination therapy of tumor-targeting Salmonella typhimurium A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 503, 3086-3092	3.4	18
23	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 506, 912-917	3.4	17
22	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018 , 53, 30-36	2.7	15
21	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. <i>Oncotarget</i> , 2018 , 9, 7774-7781	3.3	15
20	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018 , 505, 733-739	3.4	14
19	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , 2018 , 17, 627-633	4.7	13
18	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 6598-6603	4.7	13
17	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018 , 18, 840	4.8	13
16	Assessment of Anastomotic Biliary Complications in Adult Patients Undergoing High-Acuity Liver Transplant. <i>JAMA Surgery</i> , 2019 , 154, 431-439	5.4	10
15	Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cell Cycle</i> , 2018 , 17, 722-727	4.7	9
14	Rescue Diverting Loop Ileostomy: An Alternative to Emergent Colectomy in the Setting of Severe Acute Refractory IBD-Colitis. <i>Diseases of the Colon and Rectum</i> , 2018 , 61, 214-220	3.1	9
13	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019 , 27, 211-216	5.4	9
12	Tumor-targeting A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018 , 4, e00643	3.6	8

11	Minimizing central line-associated bloodstream infections in a high-acuity liver transplant intensive care unit. <i>American Journal of Infection Control</i> , 2019 , 47, 305-312	3.8	7
10	Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). <i>Tissue and Cell</i> , 2018 , 54, 144-149	2.7	6
9	Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	5
8	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018 , 3, 12	2.1	5
7	Tumor-targeting Salmonella typhimurium A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , 2018 , 119, 7827-7833	4.7	4
6	Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019 , 58, 107-111	2.7	3
5	Quantitative Measure of Intestinal Permeability Using Blue Food Coloring. <i>Journal of Surgical Research</i> , 2019 , 233, 20-25	2.5	3
4	Optimizing the Management of Abnormal Liver Function Tests after Orthotopic Liver Transplant: A Systems-Based Analysis of Health Care Utilization. <i>American Surgeon</i> , 2017 , 83, 1152-1156	0.8	3
3	Sustaining Improvement: Implementation and Spread of a Surgical Site Infection Bundle. <i>American Surgeon</i> , 2018 , 84, 1665-1669	0.8	2
2	Sustaining Improvement: Implementation and Spread of a Surgical Site Infection Bundle. <i>American Surgeon</i> , 2018 , 84, 1665-1669	0.8	2
1	Optimizing the Management of Abnormal Liver Function Tests after Orthotopic Liver Transplant: A Systems-Based Analysis of Health Care Utilization. <i>American Surgeon</i> , 2017 , 83, 1152-1156	0.8	1